Compare BGSI & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGSI | WGS |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Retail: Computer Software & Peripheral Equipment |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.6B |
| IPO Year | N/A | N/A |
| Metric | BGSI | WGS |
|---|---|---|
| Price | $178.30 | $84.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $138.13 |
| AVG Volume (30 Days) | 18.4K | ★ 862.3K |
| Earning Date | 02-25-2026 | 02-23-2026 |
| Dividend Yield | ★ 0.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | 0.07 |
| Revenue | ★ $3,101,279,000.00 | $402,190,000.00 |
| Revenue This Year | $4.03 | $41.17 |
| Revenue Next Year | $26.52 | $23.94 |
| P/E Ratio | ★ $308.32 | $1,169.64 |
| Revenue Growth | 1.42 | ★ 50.50 |
| 52 Week Low | $136.81 | $55.17 |
| 52 Week High | $178.86 | $170.87 |
| Indicator | BGSI | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 69.84 | 28.51 |
| Support Level | $159.92 | $82.09 |
| Resistance Level | $175.19 | $101.94 |
| Average True Range (ATR) | 3.80 | 6.65 |
| MACD | 0.99 | -0.53 |
| Stochastic Oscillator | 90.70 | 18.80 |
Boyd Group Services Inc is engaged in operating non-franchised collision repair centers in North America. The Company's primary line of business is automotive collision and glass repair and related services, with the majority of revenues relating to this group of similar services. This line of business operates in Canada and the U.S. and both regions exhibit similar long-term economic characteristics. he Company is also a retail auto glass operator in the United States, under the trade names Gerber Collision & Glass, Glass America, Auto Glass Service, Auto Glass Authority, and Autoglassonly.com. In addition, the Company operates a third-party administrator, Gerber National Claims Services (GNCS), that offers glass, emergency roadside, and first notice of loss services.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.